The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%, or $12 billion, from last year's negotiated Medicare spending on 15 "widely used" drugs, including Ozempic and Wegovy.

The maximum fair prices for the 15 drugs, representing some of the highest Medicare Part D spending, will take effect from Jan. 1, 2027, according to CMS.

The move brings the total number of negotiated drugs to 25 when combined with the 10 previously negotiated drugs, whose maximum fair prices will take effect from the beginning of next year.

The 15 drugs are used to treat chronic illnesses, including cancer, diabetes and asthma.

"These savings are the result of the Trump Administration's aggressive push for lower prices for Medicare beneficiaries," the CMS said.

The discounted negotiated price from the 2024 list price for Novo Nordisk's (NVO) Ozempic, Rybelsus, and Wegovy was 71%, the CMS said. These medications treat Type 2 diabetes, cardiovascular

disease, and obesity.

The highest price negotiation was 85% for Janumet and Janumet XR from Merck Sharp & Dohme, a subsidiary of Merck & Co. (MRK), to treat Type 2 diabetes.

The companies whose drug prices were negotiated include Bristol-Myers Squibb (BMY), Pfizer (PFE), AbbVie (ABBV), AstraZeneca (AZN), and Amgen (AMGN).